Neogenomics Soars 21.64% on Legal Victory, Cancer Diagnostics Dominance

Neogenomics' stock surged 21.64% in pre-market trading on September 1, 2025, driven by a significant legal victory and the potential dominance of its RaDaR® assay in the $50 billion cancer diagnostics market.

Neogenomics recently won a major lawsuit, which could pave the way for its RaDaR® assay to dominate the cancer diagnostics market. This legal victory is expected to boost the company's market position and potentially increase its revenue streams. The RaDaR® assay, which utilizes natural language processing (NLP) in healthcare, is part of a booming $16 billion industry. This development has sparked optimism among investors, leading to the stock's pre-market surge.